R&D Partner Content 7th Gene Therapy for Rare Disorders Summit returns to Boston... Accelerating Safe, Effective & Accessible Therapies in Rare Diseases
News Lilly unveils employer scheme for weight-loss drug Zepbound Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
